Filing Details

Accession Number:
0001127602-23-003104
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-02 16:15:16
Reporting Period:
2023-02-01
Accepted Time:
2023-02-02 16:15:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1721108 Sinclair A. Dunlop C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-01 500 $52.61 132,297 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 240,679 Indirect Indirect Owner (Epidarex)
Common Stock 31,855 Indirect Indirect Owner (Masa)
Footnotes
  1. The sale reported on this Form 4 was effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2022.
  2. The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
  3. The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.